2020
Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi.
Hsieh YL, Jahn A, Menzies NA, Yaesoubi R, Salomon JA, Girma B, Gunde L, Eaton JW, Auld A, Odo M, Kiyiika CN, Kalua T, Chiwandira B, Mpunga JU, Mbendra K, Corbett L, Hosseinipour MC, Cohen T, Kunkel A. Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 85: 643-650. PMID: 33177475, PMCID: PMC8564780, DOI: 10.1097/qai.0000000000002497.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIPT programIPT strategyPreventive therapyContinuous isoniazid preventive therapyMore TB casesHIV-positive adultsCases of tuberculosisAnticipated health effectsComparable health benefitsHIV/AIDSCause deathAntiretroviral therapyTB casesTB controlTB incidenceDrug costsMalawi MinistryMean reductionTuberculosisMycobacterium tuberculosisTherapyAnticipated health impactsHealth effectsHealth benefits
2013
Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis
Mills HL, Cohen T, Colijn C. Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis. Science Translational Medicine 2013, 5: 180ra49. PMID: 23576815, PMCID: PMC3714172, DOI: 10.1126/scitranslmed.3005260.Peer-Reviewed Original ResearchConceptsDrug-resistant TBIPT interventionDrug-sensitive infectionsIsoniazid-resistant TBHIV/TBRisk of progressionHigh HIV prevalenceDrug-resistant diseaseIsoniazid-resistant Mycobacterium tuberculosisSymptom-free individualsSignificant elevated riskDrug-resistant strainsWorld Health OrganizationActive TBTB controlResistant tuberculosisHIV prevalenceTuberculosis controlIPT programElevated riskHost immunityMycobacterium tuberculosisHealth OrganizationSelective suppressionIntervention
2011
Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure
Mills HL, Cohen T, Colijn C. Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure. Journal Of The Royal Society Interface 2011, 8: 1510-1520. PMID: 21508012, PMCID: PMC3163428, DOI: 10.1098/rsif.2011.0160.Peer-Reviewed Original ResearchConceptsTB diseaseLatent M. tuberculosis infectionEffects of IptHIV-endemic settingsActive tuberculosis diseaseIsoniazid preventive therapyIntact immune systemM. tuberculosis infectionWorld Health OrganizationPreventive therapyTB casesTuberculosis infectionTuberculosis diseaseClinical trialsEndemic settingsIPT programHigh riskLatent infectionSingle drugCommunity-wide levelRespiratory contactHIVImmune systemPopulation-level impactUse of IPT